Background: Salvia miltiorrhiza Bunge, a perennial medicinal plant belonging to the family Lamiaceae, is native to China and is cultivated in South Korea for its roots. Initially dependent on Chinese imports, recent cultivation advancements have expanded domestic production, however, developed varieties remain lacking. Methods and Results: The best lines were selected from among the offspring in 2010, replicated yield trials (RYT) were conducted in 2014, and local adaptability testing (LAT) was performed in 2015. The ‘Dasan’ line showed beneficial characteristics, including increased emergence rate and superior disease resistance against root rot compared with those of the local variety. Salvianolic acid B and tanshinone IIA were quantified as active ingredients using high performance liquid chromatography: these showed higher levels in ‘Dasan’, than in the local variety indicating its potential as a valuable medicinal variety. Simultaneously the dried root yield was 365 ㎏ per 10 a at four different regions, representing a 125% yield increase compared to that of the local variety. Conclusion: ‘Dasan’ shows promise as a variety of S. miltiorrhiza with superior growth, disease resistance, and high yield potential. This research plays a crucial role in establishing ‘Dasan’ as the first domestically developed S. miltiorrhiza variety in South Korea, marking a milestone in the pursuit of a standardized herbal medicine.